Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 9/20 | 0.38 |
| ▸ | HTR2A | P28223 | 9/20 | 0.38 |
| ▸ | DRD3 | P35462 | 9/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762016 | 0.85 | ABCG2 (0.44) | ABCG2MAOBLMNAPOLBALDH1A1 | |
| SCHEMBL3819757 | 0.81 | ABCG2 (0.41) | ABCG2DRD2HTR2ADRD3MAOB | |
| SCHEMBL7416843 | 0.81 | ABCG2 (0.41) | ABCG2MAOBLMNAPOLBALDH1A1 | |
| SCHEMBL14521256 | 0.79 | ABCG2 (0.39) | ABCG2DRD2HTR2ADRD3MAOB | |
| SCHEMBL2278646 | 0.77 | GSK3B (0.39) | ABCG2MAOBLMNAPOLBALDH1A1 | |
| SCHEMBL19738334 | 0.76 | EED (0.37) | ABCG2DRD2HTR2ADRD3MAOB | |
| SCHEMBL3533407 | 0.76 | NR3C1 (0.43) | DRD2HTR2ADRD3MAOBMGAM | |
| SCHEMBL10915836 | 0.76 | ABCG2 (0.43) | ABCG2HTR2AMAOBPOLBMAPK1 | |
| SCHEMBL22839334 | 0.74 | MTNR1A (0.43) | LMNAKDM4E | |
| SCHEMBL10915684 | 0.74 | ABCG2 (0.41) | ABCG2MAOBLMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662821-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-7659297-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | Bayer Schering Pharma, AG (DE) | 2010-02-09 | — | — | US | disclosed |
| US-7638515-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-29 | — | — | US | disclosed |
| CN-101248066-A | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-08-20 | — | — | CN | disclosed |
| EP-1902049-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-7329753-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2008-02-12 | — | — | US | disclosed |
| EP-1492771-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-11 | — | — | US | disclosed |
| WO-2006136461-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1670458-B1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-28 | — | — | US | disclosed |
| US-6897224-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-05-24 | — | — | US | disclosed |
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-04-28 | — | — | US | disclosed |
| WO-2005034939-A1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005003098-A1 | HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-13 | — | — | WO | disclosed |
| EP-1492771-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | SCHERIN AKTIENGESELLSCHAFT (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004058733-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
| WO-2003082827-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | IL1B, NFKBIA, BBOX1 | ABCG2 532/4885DRD2 1359/4885HTR2A 1470/4885 |
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, CYP19A1 | ABCG2 3728/4885DRD2 3556/4885HTR2A 614/4885 |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | ABCG2 520/4885DRD2 3243/4885HTR2A 1978/4885 |
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGER1, PTGES | ABCG2 2419/4885DRD2 2990/4885HTR2A 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.